Theranostics 2018; 8(10):2621-2633. doi:10.7150/thno.24469

Research Paper

Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system

Siwen Li1, Yuxi Liu1, Yalan Rui1, Liping Tang2, Samuel Achilefu3, Yueqing Gu1,✉

1. Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, 24th Tong Jia street, Nanjing 210009, Jiangsu Province, China. Phone: 86-25-83271046; Fax: 86-25-83271046.
2. Department of Bioengineering, University of Texas at Arlington, Arlington, TX, USA.
3. Department of Radiology, School of Medicine, Washington University in St. Louis, MO, USA

Abstract

Although EML4-ALK transforming fusion gene is represented in only 8% of non-small cell lung cancer (NSCLC) cases, its expression is partly responsive for the failure of current NSCLC treatments. Preventing secondary mutation of the ALK protein through direct gene manipulation could overcome NSCLC drug resistance.

Method: In this study, we developed a gold nanoshell (HAuNs) drug carrier for delivery and selective photo-thermal release of genes that target ALK and microRNA-301 in NSCLC. Additionally, the densely-coated nanoshell adsorbed high amounts of the positively-charged anticancer drug doxorubicin (DOX), generating an exciting multidimensional treatment strategy that includes gene-, thermal- and chemo- therapy.

Results: The ALK mRNA and microRNA-301 genes as the double targets exhibited the combined effect. The drug carrier system significantly improved the drug accumulation in tumor tissues due to the enhanced vascular permeability by photothermal effect, dense spherical structure and RGD peptide modification.

In vitro and in vivo results demonstrated the multiple therapeutic effects of the gold nanoshell-based system was better than the monotherapy.

Conclusion: The above results indicated the gold nanoshell-based system would be a promising translational nano-formulation platform for effective treatment of EML4-ALK-positive NSCLC.

Keywords: EML4-ALK, gold nanoshell, gene therapy, hyperthermia, chemo-therapy.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Li S, Liu Y, Rui Y, Tang L, Achilefu S, Gu Y. Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system. Theranostics 2018; 8(10):2621-2633. doi:10.7150/thno.24469. Available from http://www.thno.org/v08p2621.htm